Stewart Kay joins Adaptate Biotherapeutics as Chief Business Officer

Stewart Kay joins Adaptate Biotherapeutics as Chief Business Officer


  • Post By : Kumar Jeetendra

  • Source: Adaptate Biotherapeutics

  • Date: 28 Oct,2020

In this new role, Stewart will work as part of the Executive staff to drive Adaptate’s Business and Corporate Development activities.

Stewart Kay, CBO, Adaptate Biotherapeutics
Adaptate is developing a range of therapeutic antibodies that recognize drug targets and have the potential to modulate the activity of gamma delta T cells. Gamma delta T cells are a distinct T cell sub-type that react to molecular patterns of distress in situ and have been proven to have tremendous potential in treating cancer and other immunological disorders.

Stewart joins Adaptate with more than 20 years’ experience in business development in both biotech and big pharma. He was Chief Business Officer at Crescendo Biologics and prior to that was Senior Director, Transactions, at GlaxoSmithKline (GSK), in the Worldwide Business Development group. Stewart has broad experience over a vast array of deals across multiple therapeutic areas. He’s been responsible for a range of early and late stage clinical in- and out-licensing agreements and numerous transactions regarding pre-clinical resources and technology platforms. Before joining GSK, Stewart also held senior business development roles at Asterand plc and Evotec AG. He holds a BSc (Hons) in Biochemistry, and an MBA from Warwick University Business School.

Adaptate has recently been named one of Scrip’s ’10 To Watch’ companies at Bio-Europe Digital 2020, a nomination for emerging companies displaying promise in drug discovery and development. The opportunity to view Adaptate’s presentation can be obtained:

We have made rapid progress at Adaptate over our first year of operations. Stewart brings a wealth of business development experience and extensive knowledge of the pharma and life sciences sector. We welcome him to the Adaptate team as we enter this next phase of development of the company and progression of our pipeline.”

Dr Natalie Mount, CEO of Adaptate Biotherapeutics

I am delighted to be joining Adaptate at such an exciting time for the company. Adaptate have established themselves as leaders in developing therapeutic antibodies designed to modulate the activity of a patient’s own cytotoxic gamma delta T cells. I have been impressed at the pace of progress achieved and look forward to working with the team to realize the potential of this next generation of immunotherapy.”

Stewart Kay, CBO of Adaptate Biotherapeutics


About Author